Trial Profile

BRIGHTSTAR: A Pilot Trial of Local Consolidative Therapy (LCT) With Brigatinib in Tyrosine Kinase Inhibitor-Naive ALK-Rearranged Advanced NSCLC

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brigatinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms BRIGHTSTAR

Most Recent Events

20 Sep 2023 Planned End Date changed from 28 Jan 2024 to 28 Jan 2026.
20 Sep 2023 Planned primary completion date changed from 28 Jan 2024 to 28 Jan 2026.
12 Sep 2023 Results (n=34 from studies NCT03707938 and NCT02737501) assessing retrospective comparison of Disease burden by overall 3D tumor volume presented at the 24th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com